Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8228471 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 10 Pages |
Abstract
5-Hydroxytryptamine-3 RAs are superior to placebo and other antiemetics for prevention of emesis, but little benefit was identified for nausea prevention. 5-Hydroxytryptamine-3 RAs are suggested for prevention of emesis. Limited evidence was found regarding delayed emesis, adverse events, quality of life, or need for rescue medication. Future randomized, controlled trials should evaluate different 5-HT3 antiemetics and new agents with novel mechanisms of action such at the NK1 receptor antagonists to determine the most effective drug. Delayed nausea and vomiting should be a focus of future study, perhaps concentrating on the palliative cancer population.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Nadia M.Sc.(C.)., Brett M.Sc.(C.)., Luluel M.D., Gayathri M.Sc.(C.)., Kristopher M.D., Mark Pharm.D., Carlo Pharm.D., May M.D., Edward MBBS,